Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

March 23-24, 2018

New York, New York

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™.

Who Should Attend
This educational activity is specifically designed to meet the educational needs of community oncologists and other healthcare professionals (physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved in the therapeutic management of patients with GI cancers.

Upon completion of these educational activities, participants should be better able to:

    • Analyze the mechanism of action (MOA) and safety-efficacy profiles of currently approved and emerging oncological agents including immunotherapies for the management of GI malignancies
    • Integrate clinical trial data and evidence-based therapies for improving clinical outcomes in patients with GI malignancies
    • Evaluate the best practices and standards of care based on a multidisciplinary approach for the management of GI cancers
    • Implement the rational use of immunotherapies in patients with GI malignancies on a case-by case basis
    • Define patient populations most suitable for enrolling in GI clinical trials for progressive advanced stage GI malignancies
    • Implement optimal management strategies for both metastatic and non-metastatic GI malignancies based on personalized factors such as comorbidities, cost, disease stage, and prior therapeutic regimens